BIO0.HM Biotest GmbH & Co. KGaA
- Market cap
- -
- P/E
- -
- P/B
- -
- ROE
- -15.3%
- Dividend yield
- 0.12%
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is BIO0.HM undervalued?
Graham numberThe Graham number of Biotest GmbH & Co. KGaA cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Biotest GmbH & Co. KGaA fundamental analysis
No fundamental analysis for Biotest GmbH & Co. KGaA yet.
Biotest GmbH & Co. KGaA stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Biotest GmbH & Co. KGaA
Biotest GmbH & Co. KGaA develops, manufactures, and sells biological and biotechnological pharmaceutical products in Germany and internationally. The company specializes primarily in the therapeutic areas of clinical immunology, haematology, and intensive care medicine. Its products include Haemoctin SDH for the treatment of haemophilia A acute therapy and prophylaxis; and Haemonine for haemophilia B acute therapy and prophylaxis. The company also offers Cytotect CP biotest …
Full company profileBiotest GmbH & Co. KGaA financial statements
Biotest GmbH & Co. KGaA annual financial statements (EUR; K = thousand, M = million, B = billion, T = trillion)
| Item | 2023 | 2024 | 2025 |
|---|---|---|---|
| Income Statement | |||
| Revenue | 685M | 726M | 649M |
| Gross Profit | 280M | 224M | 69.5M |
| Operating Income | 129M | 81.9M | -75.5M |
| EBITDA | 182M | 120M | -16.8M |
| Net Income | 127M | 26.4M | -70.7M |
| Balance Sheet | |||
| Total Assets | 1.41B | 1.43B | 1.53B |
| Total Liabilities | 912M | 903M | 1.07B |
| Shareholders' Equity | 499M | 531M | 464M |
| Cash & Short-term Investments | 108M | 108M | 89.8M |
| Cash Flow | |||
| Operating Cash Flow | -2.70M | 60.9M | -145M |
| Capital Expenditure | 33.4M | 28.7M | 11.6M |
| Free Cash Flow | -36.1M | 32.2M | -157M |
| Ratios | |||
| ROE | 25.5% | 5.0% | -15.3% |
| ROA | 9.0% | 1.8% | -4.6% |
| Net Profit Margin | 18.6% | 3.6% | -10.9% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Biotest GmbH & Co. KGaA dividends
- Dividend yield
- 0.12%
- Forward dividend
- 0.04 EUR
- Payout ratio
- -
- Ex-dividend date
- Jul 22, 2026
Who owns Biotest GmbH & Co. KGaA
- Insiders 61.56%
- Institutions 0.00%
- Public & others 38.44%
- Free float 39.6M
Biotest GmbH & Co. KGaA company profile
- Company name
- Biotest GmbH & Co. KGaA
- Ticker
- BIO0.HM
- ISIN
- DE000A41YE49
- Exchange
- Hamburg Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 2,698
- Fiscal year end
- December
- Address
- Landsteinerstr. 5, Dreieich, Germany, 63303
- Phone
- 49 61 03 801 0
- Website
- biotest.com
About Biotest GmbH & Co. KGaA
Biotest GmbH & Co. KGaA develops, manufactures, and sells biological and biotechnological pharmaceutical products in Germany and internationally. The company specializes primarily in the therapeutic areas of clinical immunology, haematology, and intensive care medicine. Its products include Haemoctin SDH for the treatment of haemophilia A acute therapy and prophylaxis; and Haemonine for haemophilia B acute therapy and prophylaxis. The company also offers Cytotect CP biotest for prophylaxis of the clinical manifestation of cytomegalovirus infection in patients undergoing immunosuppressive therapy; Fovepta for immunoprophylaxis of hepatitis B in neonates; Hepatect CP for prophylaxis and immunoprophylaxis of hepatitis B; Intratect and Yimmugo for primary immune and secondary antibody deficiency syndromes, as well as autoimmune diseases, including neurological indications, chronic inflammatory demyelinating polyneuropathy, multifocal motor neuropathy, Guillain-Barré syndrome, immune thrombocytopenia, and Kawasaki syndrome; Varitect for prophylaxis and treatment of varicella zoster virus infections; and Zutectra for prophylaxis and treatment of hepatitis B reinfection following liver transplantation. In addition, it provides Albiomin and Biseko to restore and maintain circulating blood volume; Cofact for deficiency of coagulation factors; Fibrinogen to treat congenital and acquired fibrinogen deficiency; Trimodulin for community-acquired pneumonia; and Pentaglobin to treat bacterial infections. The company has a technology transfer and licensing agreement with Grifols, S.A. for the manufacture and marketing of Yimmugo, Fibrinogen, and Trimodulin. Biotest GmbH & Co. KGaA was founded in 1946 and is headquartered in Dreieich, Germany. Biotest GmbH & Co. KGaA operates as a subsidiary of Grifols Biotest Holdings GmbH.
Biotest GmbH & Co. KGaA management
4- Dr. Jorg SchuttrumpfCEO & Chairman of Management Board · born 1974
- Dirk SchuckEmployee Representative Member of Supervisory Board · born 1978
- Dr. Monika ButtkereitHead of Investor Relations
- Dr. Christina ErbHead of Corporate HR